Diabetic retinopathy (DR) is the leading cause of new-onset blindness among working-age adults in the United States. With more than 37 million Americans diagnosed with diabetes, DR affects approximately 1 in 3 diabetic patients, and roughly 1 in 10 has vision-threatening disease. For the COA, diabetic eye disease is one of the highest-frequency clinical encounters -- and one of the most important areas to master for both the exam and daily practice.
Diabetic retinopathy results from chronic hyperglycemia damaging the microvasculature of the retina. Pericyte loss, basement membrane thickening, endothelial cell damage, and breakdown of the blood-retinal barrier lead to the clinical findings seen on fundus examination. The disease is classified as non-proliferative DR (NPDR) or proliferative DR (PDR) based on the absence or presence of abnormal new vessel growth.
This guide covers the ETDRS-based classification of DR severity, the key fundus findings and what they represent pathophysiologically, the 4-2-1 rule for severe NPDR, diabetic macular edema, the COA's imaging role (wide-field photography, OCT, fluorescein angiography basics), patient education, and treatment overview.
DR Classification: NPDR and PDR
The ETDRS (Early Treatment Diabetic Retinopathy Study) classification, now simplified into the International Clinical DR Severity Scale, is the standard framework. The key distinction is whether neovascularization (abnormal new blood vessels) is present.
No Apparent DR
Level 10No retinopathy visible. Dilated fundus exam required (cannot be ruled out with undilated exam). Annual or biennial follow-up.
Mild NPDR
Level 20Microaneurysms only. Small red dots on fundus exam, most numerous in the posterior pole. First clinically visible sign of DR. Follow-up every 12 months.
Moderate NPDR
Level 35-43More than just microaneurysms but less than severe NPDR. Dot/blot hemorrhages, hard exudates, cotton-wool spots, mild venous dilation. Follow-up every 6-12 months.
Severe NPDR (4-2-1 Rule)
Level 53ANY ONE of: Hemorrhages in all 4 quadrants; Venous beading in ≥2 quadrants; IRMA in ≥1 quadrant. ~50% progress to PDR within 1 year without treatment. Follow-up every 3-4 months. Consider anti-VEGF or PRP.
Proliferative DR (PDR)
Level 61+Presence of neovascularization (NVD or NVE) anywhere on the retina or disc. Complications include vitreous hemorrhage, traction retinal detachment, and neovascular glaucoma (from rubeosis iridis). High-risk PDR (NVD ≥1/4-1/3 disc area, or any NVD with vitreous hemorrhage) requires urgent treatment.
Key Fundus Findings in Diabetic Retinopathy
| Finding | Appearance | Pathophysiology | DR Stage |
|---|---|---|---|
| Microaneurysms | Small red dots (<125 microns) | Outpouchings in capillary walls from pericyte loss | Any NPDR (first sign) |
| Dot/blot hemorrhages | Larger red dots or blot shapes in mid-retina | Intraretinal bleeding from ruptured capillaries or microaneurysms | Mild to severe NPDR |
| Flame hemorrhages | Superficial flame-shaped bleed | Bleeding into superficial nerve fiber layer | NPDR; also hypertension |
| Hard exudates | Bright yellow-white waxy deposits | Lipid and protein leakage from damaged vessels | Any NPDR; near fovea = DME risk |
| Cotton-wool spots (CWS) | Soft white fluffy patches | Axoplasmic flow obstruction from arteriolar occlusion (infarction of NFL) | Moderate NPDR; also hypertension, HIV |
| Venous beading | Irregular sausage-like venous caliber | Vascular endothelial damage causing irregular dilation | Severe NPDR (4-2-1 criterion) |
| IRMA | Fine irregular red vessels within retina (no elevation) | Intraretinal microvascular abnormalities -- shunt vessels or early neovascularization | Severe NPDR (4-2-1 criterion) |
| NVD | Fine looping vessels on/near disc surface | Neovascularization of the disc -- VEGF-driven angiogenesis from ischemia | PDR |
| NVE | Fine looping vessels on retinal surface (not disc) | Neovascularization elsewhere -- elevated from retinal surface | PDR |
Diabetic Macular Edema (DME)
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Unlike the DR staging system, DME can coexist with any level of retinopathy severity and requires separate evaluation. The COA performs OCT to detect and monitor DME -- it is far more sensitive than clinical examination alone.
DME on OCT
- Central subfield thickness (CST) >300 microns in women or >320 microns in men is typically considered thickened
- Cystic spaces (intraretinal fluid / IRF) appear as dark hyporeflective cavities within retinal layers
- Subretinal fluid (SRF) below photoreceptors may also be present
- Disorganization of inner retinal layers (DRIL) is a poor visual prognosis marker
- Hard exudates appear as focal bright hyperreflective deposits, typically in outer retinal layers
DME Treatment Overview
- Anti-VEGF injections (Eylea, Lucentis, Avastin, Vabysmo): First-line for center-involving DME with vision loss
- Intravitreal steroids (triamcinolone, ozurdex implant): Used in pseudophakic patients or anti-VEGF failures
- Focal/grid laser: For non-center-involving DME; reduces leakage from microaneurysms
- Systemic control: Blood glucose, BP, and lipid optimization reduce DME progression
Practice Diabetic Retinopathy Questions
Opterio's COA practice includes DR staging, fundus findings, DME, and patient education questions with detailed AI explanations.
COA Imaging Role in Diabetic Retinopathy
Wide-Field Fundus Photography
Wide-field and ultra-wide-field (UWF) cameras (e.g., Optos, Heidelberg) capture 100-200 degrees of the retina in a single image, compared to 45-50 degrees for standard fundus cameras. This is particularly important for DR because peripheral retinal findings (peripheral hemorrhages, NVE in the periphery, traction) are critical for staging but would be missed with standard cameras.
The COA positions the patient, focuses the camera, and captures a standardized image set. For DR monitoring, the ETDRS standard 7-field photography protocol (7 overlapping fields covering the posterior pole and midperiphery) remains the research standard; in clinical practice, 1-2 wide-field images are often used. Image quality, centering, and focus are the COA's responsibility.
OCT for DME Monitoring
The COA performs macular OCT at each DR visit to assess for DME. The scan is centered on the fovea, and the output map shows retinal thickness by sector. Central subfield thickness (CST) is the primary measurement tracked over time. The COA documents whether the scan was adequate quality (signal strength typically needs to be ≥6/10 for reliable interpretation), flags any scan artifacts, and notes any dramatic changes in CST from prior visits for the physician's attention.
Fluorescein Angiography (FA): Basics for the COA
Fluorescein angiography involves IV injection of sodium fluorescein dye and serial fundus photography as the dye circulates through retinal vessels. FA is used to identify: areas of capillary non-perfusion (ischemia), microaneurysm leakage, neovascularization (NVD/NVE), and sources of macular edema for targeted laser treatment.
The COA's role in FA: take baseline visual acuity and IOP, obtain allergy history (especially to sulfa drugs -- minor structural similarity), ensure IV access is available, prepare the camera, time the injection, and photograph the early arterial, arteriovenous, and late phases. FA can cause nausea, vomiting, and rarely anaphylaxis -- the COA must know the emergency protocol and have epinephrine available.
Patient Education: The COA's Critical Role
Key Messages for Diabetic Patients
- Diabetic retinopathy has NO early symptoms -- vision can be 20/20 with significant disease
- Annual dilated eye exams are essential even with good blood sugar control
- A1c target below 7% reduces retinopathy risk by ~35-40%
- Blood pressure control (target <130/80) is equally critical
- Report sudden vision changes, floaters, or flashes immediately
Urgent Symptoms -- Call Immediately
- Sudden floaters: May indicate vitreous hemorrhage from NVD/NVE rupture
- Shadow or curtain: May indicate traction retinal detachment
- Sudden central blur: May indicate new or worsening DME or hemorrhage
- Eye pain + red eye: May indicate neovascular glaucoma (rubeosis iridis)